New Insights into the Clinical Implications of Yes-Associated Protein in Lung Cancer: Roles in Drug Resistance, Tumor Immunity, Autophagy, and Organoid Development

Innovative advancements in lung cancer treatment have developed over the past decade with the advent of targeted and immune therapies. Yes-associated protein (YAP), an effector of the Hippo pathway, promotes the resistance of these targeted drugs and modulates tumor immunity in lung cancer. YAP is involved in autophagy in lung cancer and plays a prominent role in forming the tubular structure in lung organoids and alveolar differentiation. In this review, we discuss the central roles of YAP in lung cancer and present YAP as a novel target for treating resistance to targeted therapies and immunotherapies in lung cancer. READ ARTICLE

Cancers DOI: 10.3390/cancers13123069

Authors: Yoo G, Park D, Kim Y and Chung C.

Review Paper, group5Kirk SmithJune 17, 2021YAP, TAZ, Hippo pathway, lung cancer, drug resistance, EGFR-TKI, PD-L1, autophagy, organoid

Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor

Background: ALK rearrangements are key targets in non-small-cell lung cancer (NSCLC). Unfortunately, the optimal sequential strategy of ALK-tyrosine kinase inhibitors (TKI) remains to be defined. Testing drug sensitivity in patient derived organoids (PDOs) could support a rational drug selection in this setting. Conclusions: We present clinical evidence that PDOs are an alternative tool in oncogenic addicted tumors helping to guide treatment decisions and increasing a more personalized sequential treatment approach. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2021.39.15_suppl.e21014

Authors: Beatriz Jimenez Munarriz, Zahra Dantes, Javier De Castro, Paloma Navarro, Monica Yagüe, Arantzazu Barquin, Juan Francisco Rodriguez-Moreno, Elena Sevillano, Sergio Ruiz, Anabel del Barrio, Gema García Ledo, Miriam Dorta, Ana Collazo Lorduy, Emiliano Calvo, Jesús García-Donas, Sandra Serrano, Apoorva Manjunath, Luciana Ferreira, Barbara Hefel, Jordi Remon

Conference PaperKirk SmithMay 28, 2021Patient-derived lung cancer, organoid, therapeutic options, ALK-rearranged tumor